David Haile-Meskale

Card image cap

Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort

16 January 2018 | David Haile-Meskale, Ron Olivenstein, Toby Mcgovern, Cathy Fugere, James G. Martin
Severe atopic asthma is poorly controlled with standard treatments, including optimally dosed corticosteroids. A humanized monoclonal antibody binding immunoglobulin E, omalizumab, is approved by the US Food and Drug Administration to treat poorly controlled asthma with elevated serum IgE levels.